Systemic sclerosis and localized scleroderma—current concepts and novel targets for therapy

Seminars in Immunopathology

Volumn 38, Issue 1, 2016, Pages 87-95

  Distler, Oliver ^a   Cozzio, Antonio ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Interleukin 6; Localized scleroderma; Nintedanib; Serotonin; Soluble guanylate cyclase; Systemic sclerosis

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 6; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; NINTEDANIB; NITRIC OXIDE; RIOCIGUAT; SEROTONIN 2 RECEPTOR; SEROTONIN RECEPTOR 2B; TACROLIMUS; TERGURIDE; TOCILIZUMAB; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; GUANYLATE CYCLASE; PROTEIN KINASE INHIBITOR; SEROTONIN ANTAGONIST;

CELL ACTIVATION; CELL DIFFERENTIATION; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; ENZYME METABOLISM; ENZYME PHOSPHORYLATION; FIBROBLAST; FIBROSING ALVEOLITIS; HUMAN; INFLAMMATION; LOCALIZED SCLERODERMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; THROMBOCYTE ACTIVATION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET PHOTOTHERAPY; VASCULAR REMODELING; METABOLISM; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC;

GUANYLATE CYCLASE; HUMANS; INTERLEUKIN-6; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SEROTONIN ANTAGONISTS;

EID: 84953634986     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-015-0551-z     Document Type: Review

References (77)

1. van den Hoogen F et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 72(11):1747–1755
2. Rubio-Rivas M et al (2014) Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 44(2):208–219
3. Tyndall AJ et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69(10):1809–1815
4. Kowal-Bielecka O et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68(5):620–628
5. Kowal-Bielecka O et al (2015) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 74(Suppl 2):90
6. Beyer C et al (2010) Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 62(10):2831–2844
7. Paul SM et al (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9(3):203–214
8. Jordan S, Chung J, Distler O (2013) Preclinical and translational research to discover potentially effective antifibrotic therapies in systemic sclerosis. Curr Opin Rheumatol 25(6):679–685
9. Dobrota R, Mihai C, Distler O (2014) Personalized medicine in systemic sclerosis: facts and promises. Curr Rheumatol Rep 16(6):425
10. Allanore Y, Distler O (2015) Systemic sclerosis in 2014: advances in cohort enrichment shape future of trial design. Nat Rev Rheumatol 11(2):72–74
11. Stasch JP et al (2001) NO-independent regulatory site on soluble guanylate cyclase. Nature 410(6825):212–215
12. Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360(19):1989–2003
13. Ghofrani HA et al (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369(4):330–340
14. Beyer C et al (2012) Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis 71(6):1019–1026
15. Beyer C et al (2015) Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFbeta signalling. Ann Rheum Dis 74(7):1408–1416
16. Dees C et al (2015) Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. Ann Rheum Dis 74(8):1621–1625
17. Masuyama H et al (2009) Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertens Res 32(7):597–603
18. Iwamoto N, Distler JH, Distler O (2011) Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. Curr Rheumatol Rep 13(1):21–27
19. Bournia VK, Evangelou K, Sfikakis PP (2013) Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib. Semin Arthritis Rheum 42(4):377–390
20. Daniels CE et al (2010) Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 181(6):604–610
21. Hilberg F et al (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68(12):4774–4782
22. Maurer B et al (2014) Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. Ann Rheum Dis 73(10):1880–1887
23. Skhirtladze C et al (2008) Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 58(5):1475–1484
24. Richeldi L et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2071–2082
25. Huang J et al (2015) Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis doi: 10.1136/annrheumdis-2014-207109
26. Maurer B, Distler JH, Distler O (2013) The Fra-2 transgenic mouse model of systemic sclerosis. Vasc Pharmacol 58(3):194–201
27. Pauling JD, O’Donnell VB, McHugh NJ (2013) The contribution of platelets to the pathogenesis of Raynaud’s phenomenon and systemic sclerosis. Platelets 24(7):503–515
28. Biondi ML et al (1988) Plasma free and intraplatelet serotonin in patients with Raynaud’s phenomenon. Int J Cardiol 19(3):335–339
29. Herve P et al (1995) Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99(3):249–254
30. Stachow A, Jablonska S, Skiendzielewska A (1979) Biogenic amines derived from tryptophan in systemic and cutaneous scleroderma. Acta Derm Venereol 59(1):1–5
31. Dees C et al (2011) Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 208(5):961–972
32. Fabre A et al (2008) Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice. Eur Respir J 32(2):426–436
33. Hauso O et al (2008) The effect of terguride in carbon tetrachloride-induced liver fibrosis in rat. Exp Biol Med (Maywood) 233(11):1385–1388
34. Janssen W et al (2015) 5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure. Biomed Res Int 2015:438403
35. De Lauretis A et al (2013) Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 40(4):435–446
36. Desallais L et al (2014) Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther 16(4):R157
37. Khan K et al (2012) Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 71(7):1235–1242
38. Kitaba S et al (2012) Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 180(1):165–176
39. Le Huu D et al (2012) IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. J Invest Dermatol 132(12):2752–2761
40. Le TT et al (2014) Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis. J Immunol 193(7):3755–3768
41. Pedroza M et al (2011) Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury. PLoS One 6(7), e22667
42. Khanna D et al (2015) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis: week 48 data from the FASSCINATE trial. Ann Rheum Dis 74(Suppl2):87
43. Murray KJ, Laxer RM (2002) Scleroderma in children and adolescents. Rheum Dis Clin N Am 28(3):603–624
44. Peterson LS, Nelson AM, Su WP (1995) Classification of morphea (localized scleroderma). Mayo Clin Proc 70(11):1068–1076
45. Kreuter A et al (2009) AWMF guideline no. 013/066. Diagnosis and therapy of circumscribed scleroderma. J Dtsch Dermatol Ges 7(Suppl 6):S1–S14
46. Weibel L, Harper JI (2008) Linear morphoea follows Blaschko’s lines. Br J Dermatol 159(1):175–181
47. Blaszczyk M et al (2003) Progressive facial hemiatrophy: central nervous system involvement and relationship with scleroderma en coup de sabre. J Rheumatol 30(9):1997–2004
48. Tollefson MM, Witman PM (2007) En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol 56(2):257–263
49. Zulian F et al (2006) Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 45(5):614–620
50. Mertens JS et al (2015) Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease. Br J Dermatol 172(3):722–728
51. Leitenberger JJ et al (2009) Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol 145(5):545–550
52. Eisendle K, Grabner T, Zelger B (2007) Morphoea: a manifestation of infection with Borrelia species? Br J Dermatol 157(6):1189–1198
53. Dillon WI, Saed GM, Fivenson DP (1995) Borrelia burgdorferi DNA is undetectable by polymerase chain reaction in skin lesions of morphea, scleroderma, or lichen sclerosus et atrophicus of patients from North America. J Am Acad Dermatol 33(4):617–620
54. Horger M et al (2008) MRI findings in deep and generalized morphea (localized scleroderma). AJR Am J Roentgenol 190(1):32–39
55. Kirchgesner T et al (2015) Eosinophilic fasciitis: typical abnormalities, variants and differential diagnosis of fasciae abnormalities using MR imaging. Diagn Interv Imaging 96(4):341–348
56. Zwischenberger BA, Jacobe HT (2011) A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol 65(5):925–941
57. Kroft EB et al (2009) Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol 10(3):181–187
58. Mancuso G, Berdondini RM (2005) Localized scleroderma: response to occlusive treatment with tacrolimus ointment. Br J Dermatol 152(1):180–182
59. Stefanaki C et al (2008) Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study. J Dermatol 35(11):712–718
60. Cunningham BB et al (1998) Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 39(2 Pt 1):211–215
61. Pope E et al (2011) Topical imiquimod 5% cream for pediatric plaque morphea: a prospective, multiple-baseline, open-label pilot study. Dermatology 223(4):363–369
62. Kreuter A et al (2006) A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 54(3):440–447
63. Gordon Spratt EA et al (2015) Phototherapy, photodynamic therapy and photophoresis in the treatment of connective-tissue diseases: a review. Br J Dermatol 173(1):19–30
64. Vasquez R et al (2014) Recurrence of morphea after successful ultraviolet A1 phototherapy: a cohort study. J Am Acad Dermatol 70(3):481–488
65. Fett N, Werth VP (2011) Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol 64(2):231–42, quiz 243–4
66. Joly P et al (1994) Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol 130(5):663–664
67. Zulian F et al (2011) Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 63(7):1998–2006
68. Uziel Y et al (2000) Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 136(1):91–95
69. Kreuter A et al (2005) Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol 141(7):847–852
70. Weibel L et al (2006) Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatol 155(5):1013–1020
71. Neustadter JH et al (2009) Extracorporeal photochemotherapy for generalized deep morphea. Arch Dermatol 145(2):127–130
72. Pileri A et al (2014) Generalized morphea successfully treated with extracorporeal photochemotherapy (ECP). Dermatol Online J 20(1):21258
73. Schlaak M et al (2008) Successful therapy of a patient with therapy recalcitrant generalized bullous scleroderma by extracorporeal photopheresis and mycophenolate mofetil. J Eur Acad Dermatol Venereol 22(5):631–633
74. Alecu M et al (1998) The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localised and systemic sclerosis. Rom J Intern Med 36(3–4):251–259
75. Ihn H et al (1995) Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 287(2):193–197
76. Nagaoka T et al (2000) Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma. J Rheumatol 27(8):1917–1921
77. Zheng XY et al (1998) Expression of platelet-derived growth factor B-chain and platelet-derived growth factor beta-receptor in fibroblasts of scleroderma. J Dermatol Sci 18(2):90–97